An APOBEC3A-Cas9 base editor with minimized bystander and off-target activities

Base editor technology, which uses CRISPR–Cas9 to direct cytidine deaminase enzymatic activity to specific genomic loci, enables the highly efficient introduction of precise cytidine-to-thymidine DNA alterations. However, existing base editors create unwanted C-to-T alterations when more than one C is present in the enzyme's five-base-pair editing window. Here we describe a strategy for reducing bystander mutations using an engineered human APOBEC3A (eA3A) domain, which preferentially deaminates cytidines in specific motifs according to a TCR>TCY>VCN hierarchy. In direct comparisons with the widely used base editor 3 (BE3) fusion in human cells, our eA3A-BE3 fusion exhibits similar activities on cytidines in TC motifs but greatly reduced editing on cytidines in other sequence contexts. eA3A-BE3 corrects a human β-thalassemia promoter mutation with much higher (>40-fold) precision than BE3. We also demonstrate that eA3A-BE3 shows reduced mutation frequencies on known off-target sites of BE3, even when targeting promiscuous homopolymeric sites.

[1]  Rommie E. Amaro,et al.  Structural basis for targeted DNA cytosine deamination and mutagenesis by APOBEC3A and APOBEC3B , 2016, Nature Structural &Molecular Biology.

[2]  Bei Yang,et al.  Enhanced base editing by co-expression of free uracil DNA glycosylase inhibitor , 2017, Cell Research.

[3]  Jaewoong Hwang,et al.  Rescue of high-specificity Cas9 variants using sgRNAs with matched 5’ nucleotides , 2017, Genome Biology.

[4]  B. Eng,et al.  Three New β-Globin Gene Promoter Mutations Identified Through Newborn Screening , 2007 .

[5]  Zhi Zhang,et al.  A Novel Promoter Mutation (HBB: c.-75G>T) Was Identified as a Cause of β+-Thalassemia , 2015, Hemoglobin.

[6]  Rommie E. Amaro,et al.  The local dinucleotide preference of APOBEC3G can be altered from 5'-CC to 5'-TC by a single amino acid substitution. , 2013, Journal of molecular biology.

[7]  A. Kondo,et al.  Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems , 2016, Science.

[8]  David R. Liu,et al.  Evolved Cas9 variants with broad PAM compatibility and high DNA specificity , 2018, Nature.

[9]  S. Hubbard,et al.  A DNA Sequence Recognition Loop on APOBEC3A Controls Substrate Specificity , 2014, PloS one.

[10]  Kevin T. Zhao,et al.  Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions , 2017, Nature Biotechnology.

[11]  Kevin T. Zhao,et al.  Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity , 2017, Science Advances.

[12]  C. Schiffer,et al.  The ssDNA Mutator APOBEC3A Is Regulated by Cooperative Dimerization. , 2015, Structure.

[13]  Akihiko Kondo,et al.  Targeted base editing in rice and tomato using a CRISPR-Cas9 cytidine deaminase fusion , 2017, Nature Biotechnology.

[14]  Jeffry D. Sander,et al.  CRISPR-Cas systems for editing, regulating and targeting genomes , 2014, Nature Biotechnology.

[15]  David R. Liu,et al.  Improving the DNA specificity and applicability of base editing through protein engineering and protein delivery , 2017, Nature Communications.

[16]  David A. Scott,et al.  In vivo genome editing using Staphylococcus aureus Cas9 , 2015, Nature.

[17]  Jennifer A. Doudna,et al.  Enhanced proofreading governs CRISPR-Cas9 targeting accuracy , 2017, Nature.

[18]  Jin-Soo Kim,et al.  Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases , 2014, Bioinform..

[19]  Daesik Kim,et al.  Highly efficient RNA-guided base editing in mouse embryos , 2017, Nature Biotechnology.

[20]  Dan Liu,et al.  Correction of β-thalassemia mutant by base editor in human embryos , 2017, Protein & Cell.

[21]  Matthew C. Canver,et al.  Analyzing CRISPR genome-editing experiments with CRISPResso , 2016, Nature Biotechnology.

[22]  Gaelen T. Hess,et al.  Directed evolution using dCas9-targeted somatic hypermutation in mammalian cells , 2016, Nature Methods.

[23]  M. Wang,et al.  AID up-mutants isolated using a high-throughput screen highlight the immunity/cancer balance limiting DNA deaminase activity , 2009, Nature Structural &Molecular Biology.

[24]  C. Schiffer,et al.  Crystal structure of APOBEC3A bound to single-stranded DNA reveals structural basis for cytidine deamination and specificity , 2017, Nature Communications.

[25]  E. Welker,et al.  Crossing enhanced and high fidelity SpCas9 nucleases to optimize specificity and cleavage , 2017, Genome Biology.

[26]  Randall J. Platt,et al.  Therapeutic genome editing: prospects and challenges , 2015, Nature Medicine.

[27]  J. Doudna,et al.  The new frontier of genome engineering with CRISPR-Cas9 , 2014, Science.

[28]  J. Keith Joung,et al.  731. High-Fidelity CRISPR-Cas9 Nucleases with No Detectable Genome-Wide Off-Target Effects , 2016 .

[29]  B. Eng,et al.  Three new beta-globin gene promoter mutations identified through newborn screening. , 2007, Hemoglobin.

[30]  David R. Liu,et al.  Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage , 2016, Nature.

[31]  Daesik Kim,et al.  Genome-wide target specificities of CRISPR RNA-guided programmable deaminases , 2017, Nature Biotechnology.

[32]  J F Glenn,et al.  Prospects and challenges. , 1967, The Journal of urology.

[33]  Yuting Tan,et al.  Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia , 2016, Proceedings of the National Academy of Sciences.

[34]  J. Joung,et al.  High-fidelity CRISPR-Cas9 variants with undetectable genome-wide off-targets , 2015, Nature.

[35]  Martin J. Aryee,et al.  GUIDE-Seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases , 2014, Nature Biotechnology.